Agenus Inc. (NASDAQ:AGEN) Stock Has Average Target Price of $24.50 According to Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $24.50.

Several brokerages recently issued reports on AGEN. Chardan Capital reaffirmed a “buy” rating and set a $40.00 price target on shares of Agenus in a report on Monday, October 5th. B. Riley Financial reissued a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently modified their holdings of the company. Everhart Financial Group Inc. acquired a new position in Agenus in the 3rd quarter worth about $100,000. Globeflex Capital L P acquired a new stake in shares of Agenus during the second quarter valued at about $1,281,000. Bank of New York Mellon Corp acquired a new stake in shares of Agenus during the second quarter valued at about $311,000. Bank of America Corp DE boosted its stake in shares of Agenus by 796.7% during the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 105,536 shares in the last quarter. Finally, Redwood Family Wealth LLC bought a new stake in shares of Agenus during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Stock Down 3.1%

Agenus stock opened at $7.43 on Tuesday. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31. The business’s 50-day moving average price is $7.83 and its two-hundred day moving average price is $5.33. The stock has a market cap of $335.55 million, a PE ratio of 2.88 and a beta of 1.31.

Agenus (NASDAQ:AGEN) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. As a group, analysts expect that Agenus will post -0.30 earnings per share for the current year.

About Agenus

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.